We are live on ! Find out more
Verdad Advisers

Verdad Advisers Portfolio holdings

AUM $93.2M Turnover 65.2%
1-Year Est. Return 54.64%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+54.64%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$93.2M
AUM Growth
-$11.2M
Cap. Flow
-$3.41M
Cap. Flow %
-3.66%
Top 10 Hldgs %
18.32%
Holding
296
New
86
Increased
36
Reduced
56
Closed
107
Avg Time Held
0.3 years
Top 10 Avg Time Held
0.1 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$2.14M
2
GWW icon
W.W. Grainger
GWW
+$1.85M
3
FTNT icon
Fortinet
FTNT
+$1.82M
4
SGP icon
SpyGlass Pharma
SGP
+$1.4M
5
ATHM icon
Autohome
ATHM
+$1.36M

Top Sells

Rank Stock Value
1
CMCSA icon
Comcast
CMCSA
+$2.08M
2
CLDT icon
Chatham Lodging
CLDT
+$1.85M
3
AMN icon
AMN Healthcare
AMN
+$1.68M
4
BLTE icon
Belite Bio
BLTE
+$1.62M
5
VSNT icon
Versant Media Group
VSNT
+$1.57M

Sector Composition

Rank Sector Weight
1 Healthcare 38.83%
2 Technology 23.96%
3 Financials 11.44%
4 Communication Services 7.28%
5 Consumer Discretionary 4.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
XFOR icon
26
X4 Pharmaceuticals
XFOR
$306M
$937K 1.01%
323,166
-28,927
-8% -$112K
2026 Q2
1 quarter
OPY icon
27
Oppenheimer Holdings
OPY
$886M
$929K 1%
7,873
-800
-9% -$92.4K
2026 Q1
2 quarters
CSCO icon
28
Cisco
CSCO
$357B
$928K 1%
8,624
-1,683
-16% -$190K
2026 Q2
1 quarter
ALL icon
29
Allstate
ALL
$66.1B
$887K 0.95%
4,000
+721
+22% +$183K
2026 Q2
1 quarter
PTRN icon
30
Pattern Group
PTRN
$3.27B
$841K 0.9%
+49,005
New +$1.1M
2026 Q3
0 quarters
SEIC icon
31
SEI Investments
SEIC
$11.9B
$821K 0.88%
+8,002
New +$830K
2026 Q3
0 quarters
JANX icon
32
Janux Therapeutics
JANX
$617M
$820K 0.88%
47,479
+7,093
+18% +$119K
2026 Q2
1 quarter
NTAP icon
33
NetApp
NTAP
$31B
$800K 0.86%
+3,810
New +$703K
2026 Q3
0 quarters
JBIO icon
34
Jade Biosciences
JBIO
$1.06B
$792K 0.85%
56,377
-7
-0% -$140
2026 Q2
1 quarter
CHYM icon
35
Chime Financial
CHYM
$11.6B
$786K 0.84%
+29,515
New +$818K
2026 Q3
0 quarters
HNGE icon
36
Hinge Health
HNGE
$8.6B
$774K 0.83%
+7,959
New +$698K
2026 Q3
0 quarters
CLDX icon
37
Celldex Therapeutics
CLDX
$2.15B
$760K 0.82%
23,449
+2,745
+13% +$105K
2026 Q2
1 quarter
MOV icon
38
Movado Group
MOV
$654M
$751K 0.81%
22,565
+3,803
+20% +$136K
2026 Q1
2 quarters
LIFE icon
39
Ethos Technologies
LIFE
$2.03B
$738K 0.79%
+21,971
New +$655K
2026 Q3
0 quarters
SEPN icon
40
Septerna
SEPN
$1.84B
$720K 0.77%
18,403
+5,433
+42% +$206K
2026 Q2
1 quarter
APPF icon
41
AppFolio
APPF
$7.21B
$702K 0.75%
+3,501
New +$695K
2026 Q3
0 quarters
MSM icon
42
MSC Industrial Direct
MSM
$5.76B
$701K 0.75%
+5,666
New +$692K
2026 Q3
0 quarters
EWTX icon
43
Edgewise Therapeutics
EWTX
$4.37B
$691K 0.74%
17,012
-10,222
-38% -$434K
2026 Q1
2 quarters
OOMA icon
44
Ooma
OOMA
$466M
$688K 0.74%
33,675
+865
+3% +$18.5K
2026 Q1
2 quarters
MNPR icon
45
Monopar Therapeutics
MNPR
$468M
$670K 0.72%
+8,409
New +$902K
2026 Q3
0 quarters
BLTE icon
46
Belite Bio
BLTE
$5.17B
$644K 0.69%
3,795
-9,963
-72% -$1.62M
2026 Q1
2 quarters
SNX icon
47
TD Synnex
SNX
$17.3B
$639K 0.69%
2,489
-291
-10% -$74.3K
2026 Q1
2 quarters
CRWD icon
48
CrowdStrike
CRWD
$235B
$636K 0.68%
+2,404
New +$510K
2026 Q3
0 quarters
RDVT icon
49
Red Violet
RDVT
$1.09B
$622K 0.67%
+7,872
New +$556K
2026 Q3
0 quarters
TGT icon
50
Target
TGT
$75.1B
$609K 0.65%
+3,885
New +$584K
2026 Q3
0 quarters

Similar funds

Verdad Advisers's Q3 2026 Portfolio in Review

As of Q3 2026, Verdad Advisers held 296 positions worth $93.2M, down 11% from $104M the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Verdad Advisers withdrew a net $3.41M in Q3 2026, closing 107 positions and reducing 56 holdings. Its most notable exit was Comcast, an estimated $2.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 51% a quarter earlier, followed by Technology and Financials.

Against the trend, Verdad Advisers opened a new position in Visa worth $2.11M.

  • Verdad Advisers's largest Q3 2026 buy was Visa: 5,867 shares worth $2.11M.
  • Verdad Advisers added most to Spero Therapeutics in Q3 2026, an estimated $1.02M increase.
  • Verdad Advisers's biggest Q3 2026 reduction was Belite Bio, cutting an estimated $1.62M.
  • Verdad Advisers fully exited Comcast in Q3 2026, selling an estimated $2.08M.
  • Verdad Advisers's ten largest holdings make up 18% of its $93.2M portfolio in Q3 2026.
  • Verdad Advisers opened 86 new positions and closed 107 in Q3 2026.
  • Verdad Advisers's portfolio value fell 11% quarter-over-quarter to $93.2M.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.